Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. If you have diabetes and notice changes in urination, swelling, or fatigue, consult your healthcare provider promptly.

Diabetic Nephropathy: Kidney Health and Diabetes

Creator: Editorial Team
Published: 2026-03-28

Last updated: March 2026 | Reviewed by MDTalks Editorial Team

Diabetes is the leading cause of chronic kidney disease (CKD) and kidney failure in the United States. Diabetic nephropathy, or diabetic kidney disease (DKD), develops when chronically elevated blood sugar damages the tiny blood vessels in the kidneys’ filtration units (glomeruli). Approximately 25% to 40% of people with diabetes develop some degree of kidney disease during their lifetime. Early detection through annual screening and aggressive management can significantly slow progression and, in many cases, prevent kidney failure.

How Diabetes Damages the Kidneys

The kidneys contain approximately one million filtering units called nephrons. Each nephron contains a glomerulus, a cluster of tiny blood vessels that filters waste and excess fluid from the blood. Chronic hyperglycemia damages these vessels through several mechanisms:

Hyperfiltration: Elevated blood sugar causes the kidneys to work harder, increasing pressure within the glomeruli
Glycation of proteins: Excess glucose binds to structural proteins in the kidney, altering their function
Inflammation and oxidative stress: Hyperglycemia triggers inflammatory pathways that damage kidney tissue
Hypertension: High blood pressure, common in diabetes, compounds the vascular damage

Over years, this damage causes the glomeruli to leak protein (albumin) into the urine and progressively lose their filtering capacity.

Stages of Diabetic Kidney Disease

Stage	Kidney Function (eGFR)	Albumin in Urine (ACR)	Clinical Significance
1	Normal or high (>90)	Mildly increased (30–300 mg/g)	Early damage; often no symptoms
2	Mildly decreased (60–89)	Moderately increased	Still largely asymptomatic
3a	Mild-moderate decrease (45–59)	May increase further	Complications begin to emerge
3b	Moderate-severe decrease (30–44)	Often elevated	Medication adjustments needed
4	Severely decreased (15–29)	Significantly elevated	Preparation for kidney replacement
5	Kidney failure (<15)	Very high	Dialysis or transplant required

Screening

The ADA recommends annual screening for all people with diabetes:

Type 2 diabetes: Begin screening at diagnosis (kidney disease may already be present)
Type 1 diabetes: Begin screening 5 years after diagnosis

Two tests are used together:

Urinary albumin-to-creatinine ratio (ACR): Detects albumin leakage. Normal is below 30 mg/g; 30–300 mg/g indicates moderately increased albuminuria; above 300 mg/g indicates severely increased albuminuria.
Estimated glomerular filtration rate (eGFR): Calculated from a blood creatinine test. Normal is above 90; below 60 sustained over 3+ months indicates CKD.

Both tests are needed because some patients have declining eGFR without albuminuria, and vice versa.

For related complication screening, see Diabetic Neuropathy: Symptoms, Prevention, Treatment and Diabetic Retinopathy: Protecting Your Vision.

Prevention and Slowing Progression

Glycemic Control

Optimizing blood sugar is fundamental. The 2026 ADA Standards reinforce that intensive glycemic management reduces the risk and slows the progression of diabetic kidney disease. However, as kidney function declines, some medications require dose adjustment and hypoglycemia risk may increase.

Blood Pressure Management

Hypertension accelerates kidney damage. The 2026 ADA Standards encourage a systolic blood pressure goal below 120 mmHg for individuals with high cardiovascular or kidney risk. Treatment with ACE inhibitors or angiotensin II receptor blockers (ARBs) is recommended for patients with diabetes and albuminuria, as these medications reduce intraglomerular pressure and slow nephropathy progression.

SGLT2 Inhibitors

SGLT2 inhibitors have demonstrated powerful kidney-protective effects in multiple trials:

CREDENCE (canagliflozin): 30% reduction in kidney failure risk
DAPA-CKD (dapagliflozin): 39% reduction in kidney disease progression
EMPA-KIDNEY (empagliflozin): Significant reduction in kidney disease progression

The ADA now recommends SGLT2 inhibitors for patients with type 2 diabetes and CKD, regardless of A1C level. See SGLT2 Inhibitors: How They Work for Diabetes.

GLP-1 Receptor Agonists

GLP-1 receptor agonists also provide kidney protection by slowing albuminuria progression and reducing kidney events, in addition to their glucose-lowering and cardiovascular benefits. See GLP-1 Medications: Ozempic, Mounjaro, and Beyond.

Lifestyle Measures

Sodium restriction: Limiting sodium to below 2,300 mg daily reduces blood pressure and kidney workload
Protein intake: Moderate protein intake (0.8 g/kg/day) may slow kidney decline in advanced CKD; discuss with your provider and dietitian
Smoking cessation: Smoking accelerates kidney disease progression
Regular exercise: Improves cardiovascular health and blood pressure control

Symptoms to Watch For

Early diabetic kidney disease is typically silent. Symptoms appear as kidney function significantly declines:

Swelling in feet, ankles, hands, or face (edema)
Foamy or bubbly urine (suggests protein in urine)
Fatigue and weakness
Nausea or vomiting
Loss of appetite
Difficulty concentrating
Itching
Increased or decreased urination

If you notice any of these symptoms, consult your healthcare provider promptly.

For comprehensive management, see the Complete Guide to Diabetes Management in 2026.

Key Takeaways

Diabetes is the leading cause of kidney failure in the United States, affecting 25%–40% of people with diabetes.
Annual screening with urinary ACR and eGFR is recommended for all people with diabetes, starting at diagnosis for type 2 and after 5 years for type 1.
Glycemic control, blood pressure management (ACE inhibitors/ARBs), and SGLT2 inhibitors are the three pillars of kidney protection.
SGLT2 inhibitors are now recommended for diabetic kidney disease regardless of A1C level.
Early diabetic kidney disease has no symptoms; screening catches it before irreversible damage occurs.
Consult your healthcare provider for regular kidney function monitoring and to optimize your treatment plan.

Sources

American Diabetes Association. “11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes — 2026.” Diabetes Care, January 2026. diabetes.org
National Institute of Diabetes and Digestive and Kidney Diseases. “Diabetic Kidney Disease.” niddk.nih.gov
Heerspink HJL, et al. “Dapagliflozin in Patients with Chronic Kidney Disease.” NEJM, 2020.

This article is part of the MDTalks Diabetes Hub. See also AI Answers About Kidney Disease and AI Answers About Diabetes.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider for kidney health monitoring and management.